JP2018023397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018023397A5 JP2018023397A5 JP2017194380A JP2017194380A JP2018023397A5 JP 2018023397 A5 JP2018023397 A5 JP 2018023397A5 JP 2017194380 A JP2017194380 A JP 2017194380A JP 2017194380 A JP2017194380 A JP 2017194380A JP 2018023397 A5 JP2018023397 A5 JP 2018023397A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- xbp
- peptide consisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 102000008165 X-Box Binding Protein 1 Human genes 0.000 claims 32
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 21
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims 16
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims 16
- 102100032831 Protein ITPRID2 Human genes 0.000 claims 16
- 210000002865 immune cell Anatomy 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5818008P | 2008-06-02 | 2008-06-02 | |
| US61/058,180 | 2008-06-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017013407A Division JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018214477A Division JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018023397A JP2018023397A (ja) | 2018-02-15 |
| JP2018023397A5 true JP2018023397A5 (enExample) | 2018-05-24 |
| JP6438100B2 JP6438100B2 (ja) | 2018-12-12 |
Family
ID=41398806
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512566A Withdrawn JP2011523560A (ja) | 2008-06-02 | 2009-06-01 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017194380A Active JP6438100B2 (ja) | 2008-06-02 | 2017-10-04 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512566A Withdrawn JP2011523560A (ja) | 2008-06-02 | 2009-06-01 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2014262194A Active JP6085289B2 (ja) | 2008-06-02 | 2014-12-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2017013407A Active JP6224280B2 (ja) | 2008-06-02 | 2017-01-27 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018214477A Active JP6796123B2 (ja) | 2008-06-02 | 2018-11-15 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2020189192A Active JP7321137B2 (ja) | 2008-06-02 | 2020-11-13 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| JP2023120931A Pending JP2023134812A (ja) | 2008-06-02 | 2023-07-25 | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9096681B2 (enExample) |
| EP (2) | EP2300034B1 (enExample) |
| JP (7) | JP2011523560A (enExample) |
| CN (1) | CN102112147B (enExample) |
| CA (2) | CA2726804C (enExample) |
| WO (1) | WO2009149021A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2300034B1 (en) * | 2008-06-02 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia |
| CA2888803A1 (en) * | 2012-11-05 | 2014-05-08 | Jooeun Bae | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| EP2956481B1 (en) * | 2013-02-15 | 2020-07-01 | The Johns Hopkins University | Antigen-specific t cell redirectors |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| CN107394201B (zh) | 2016-05-09 | 2022-03-25 | 日亚化学工业株式会社 | 镍钴复合氢氧化物的制造方法及非水电解质二次电池用正极活性物质的制造方法 |
| CN106093393A (zh) * | 2016-06-02 | 2016-11-09 | 滨州医学院 | 一种基于XBP1和XBP1s表达水平的检测胃癌组织的试剂盒 |
| US12059463B2 (en) | 2017-10-24 | 2024-08-13 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| CN115040663B (zh) * | 2022-06-15 | 2023-12-12 | 上海交通大学医学院附属仁济医院 | 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| EP0585368B1 (en) | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| ES2137354T3 (es) | 1993-01-12 | 1999-12-16 | Biogen Inc | Moleculas de anticuerpo anti-vla4 recombinante. |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU6802801A (en) * | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| JP2005503118A (ja) | 2001-02-14 | 2005-02-03 | ジェンザイム・コーポレーション | 改変ペプチドリガンド |
| US7041499B2 (en) * | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US6979720B2 (en) | 2002-05-03 | 2005-12-27 | E. I. Du Pont De Nemours And Company | manufacture of certain cyclic ester oligomers |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| WO2005037855A2 (en) | 2003-10-17 | 2005-04-28 | Pecos Labs, Inc. | T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same |
| SI2301576T1 (sl) * | 2004-03-29 | 2013-02-28 | Abbott Biotherapeutics Corp. | Terapevtska uporaba protiteles proti CS1 |
| US7514237B2 (en) * | 2004-09-02 | 2009-04-07 | Wyeth | Systems and methods for protein production |
| US7842293B2 (en) | 2006-08-07 | 2010-11-30 | Facet Biotech Corporation | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| EP2942057A1 (en) * | 2006-08-07 | 2015-11-11 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| EP2300034B1 (en) | 2008-06-02 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pharmaceutical composition for use in treating or preventing multiple myeloma or waldenstrom's macroglobulinemia |
| CA2888803A1 (en) | 2012-11-05 | 2014-05-08 | Jooeun Bae | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
-
2009
- 2009-06-01 EP EP09759182.0A patent/EP2300034B1/en active Active
- 2009-06-01 CN CN200980130349.4A patent/CN102112147B/zh active Active
- 2009-06-01 US US12/995,661 patent/US9096681B2/en active Active
- 2009-06-01 CA CA2726804A patent/CA2726804C/en active Active
- 2009-06-01 WO PCT/US2009/045866 patent/WO2009149021A2/en not_active Ceased
- 2009-06-01 CA CA3138282A patent/CA3138282A1/en active Pending
- 2009-06-01 EP EP18162674.8A patent/EP3384919A1/en active Pending
- 2009-06-01 JP JP2011512566A patent/JP2011523560A/ja not_active Withdrawn
-
2014
- 2014-12-25 JP JP2014262194A patent/JP6085289B2/ja active Active
-
2015
- 2015-06-29 US US14/754,456 patent/US11083783B2/en active Active
-
2017
- 2017-01-27 JP JP2017013407A patent/JP6224280B2/ja active Active
- 2017-10-04 JP JP2017194380A patent/JP6438100B2/ja active Active
-
2018
- 2018-11-15 JP JP2018214477A patent/JP6796123B2/ja active Active
-
2020
- 2020-11-13 JP JP2020189192A patent/JP7321137B2/ja active Active
-
2021
- 2021-07-08 US US17/370,412 patent/US20220031821A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120931A patent/JP2023134812A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018023397A5 (enExample) | ||
| JP2014240404A5 (enExample) | ||
| PE20251185A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| AR127118A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| JP2015131795A5 (enExample) | ||
| JP2017165733A5 (enExample) | ||
| WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
| JP2017048194A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| PE20181490A1 (es) | Tratamientos contra el cancer de utero | |
| JP2014532649A5 (enExample) | ||
| JP2020511672A5 (enExample) | ||
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| JP2016519933A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| JP2017511135A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| RU2021132734A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2015510393A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) |